I am a top-tier Biotechnology Investigator and Executive with extensive strategic and leadership experience and demonstrated success in bench to IND development of small molecule and biologic drugs for oncology, autoimmunity, chronic inflammation and fibrosis. I have deep experience in therapeutic area analysis and strategic development, opportunity assessment, due diligence, and alignment of research, commercial and clinical strategies. My recent accomplishments include working intensively with CoStim Pharmaceuticals' executive team to prioritize and launch that company's Cancer Immunotherapeutics portfolio. More recently I embedded with X-Chem Inc to create X-Rx Discovery, an asset-centric biotechnology company. As CSO, I built that company from conception to full portfolio execution, including medicinal chemistry, assay development, ADME/DMPK support, efficacy and toxicity assessment. I drove two lead programs, targeting autotaxin and BTK, from hit through lead optimization, and selected lead candidates for IND enablement. More broadly, I have consulted extensively across the academic, biotechnology and venture capital environments. My contributions to corporate development include comprehensive research planning, identifying funding sources, evaluating the therapeutic rationale for pathways targeted in specific diseases (oncology, inflammation, autoimmunity, metabolic disease, cardiovascular disease, asthma and many others), review of specific molecular targets, and identifying key academic and corporate partners for specific programs. My ability to work so broadly across the bio-pharmaceutical landscape is grounded in my long and highly successful career in the industry, notably at Biogen Idec Inc.My CV may be found at www.sugarconebiotech.com